Get the Stockscreener App
6.72
1.97%
0.13
After Hours:
6.72
Personalis Inc stock is traded at $6.72, with a volume of 1.99M.
It is up +1.97% in the last 24 hours and down -18.15% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$6.59
Open:
$6.66
24h Volume:
1.99M
Relative Volume:
1.39
Market Cap:
$703.13M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.9867
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-14.29%
1M Performance:
-18.15%
6M Performance:
+14.87%
1Y Performance:
+88.24%
1-Day Range:
$6.6505
$7.105
1-Week Range:
$6.56
$8.4156
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.72 | 703.13M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal - BioSpace
Personalis (PSNL) Publishes Promising Study on Cancer Detection Method - GuruFocus
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® - Business Wire
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Growth Report: Is Personalis Inc showing insider buyingEarnings Growth Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen - MarketBeat
Momentum Shift: Is Personalis Inc benefiting from interest rate changesJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is Personalis Inc. stock attractive after correctionTrade Risk Summary & Weekly High Momentum Picks - Naître et grandir
Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis
Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
PSNL: Morgan Stanley Maintains Equal-Weight, Lowers Price Target - GuruFocus
Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Short Interest Up 21.2% in February - MarketBeat
Personalis (NASDAQ:PSNL) Shares Gap DownTime to Sell? - MarketBeat
Will Personalis Inc. outperform small cap indexesBear Alert & Free Verified High Yield Trade Plans - mfd.ru
Breaking Down Personalis: 5 Analysts Share Their Views - Sahm
Personalis, Inc. (NASDAQ:PSNL) Q4 2025 Earnings Call Transcript - Insider Monkey
Personalis (NASDAQ:PSNL) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Personalis 2025 Financial Results: Revenue, Loss, and 2026 ForecastNews and Statistics - IndexBox
Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews
Personalis (NASDAQ:PSNL) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Personalis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham raises Personalis stock price target on reimbursement wins By Investing.com - Investing.com Nigeria
Needham raises Personalis stock price target on reimbursement wins - Investing.com Australia
PSNL Stock Sees Price Target Increase by Needham | PSNL Stock Ne - GuruFocus
Personalis stock price target reaffirmed at $13 by BTIG on MRD growth - Investing.com South Africa
Personalis Q4 Earnings Call Highlights - MarketBeat
Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust C - GuruFocus
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... By GuruFocus - Investing.com Canada
Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Personalis: Q4 Earnings Snapshot - theheraldreview.com
Personalis (PSNL) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Personalis Q4 2025 sees EPS beat but revenue miss - Investing.com
Personalis (PSNL) Offers FY26 Revenue Forecast Below Expectations - GuruFocus
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
PSNL Achieves Strong Q4 Revenue and Prepares for Significant Gro - GuruFocus
Personalis Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Progyny Inc. (PGNY) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
[10-K] Personalis, Inc. Files Annual Report | PSNL SEC FilingForm 10-K - Stock Titan
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Breakdown: Personalis Q4 - Benzinga
Personalis (NASDAQ: PSNL) details 2025 results and 2026 growth plan - Stock Titan
Personalis, Inc. Provides Earnings Guidance for the Full Year of 2026 - marketscreener.com
BRIEF-Personalis Q4 Net Income USD -23.812 Million - TradingView
Personalis: Overview of Fourth Quarter Financial Results - Bitget
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (PSNL) CEO gains 33,333 performance-based stock options - Stock Titan
How Personalis Inc. stock performs in weak economyJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Personalis (NASDAQ:PSNL) Shares Down 4.8%Should You Sell? - MarketBeat
Aberdeen Group plc Increases Stock Position in Personalis, Inc. $PSNL - MarketBeat
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):